StreetInsider.com News Articles

Form S-3 ADC Therapeutics SA

Tue, 10 Mar 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260310/26140569.html

Form S-3 ADC Therapeutics SA

Tue, 10 Mar 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260310/26140569.html

Form ARS ADC Therapeutics SA For: Dec 31

Tue, 10 Mar 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260310/26140236.html

Form ARS ADC Therapeutics SA For: Dec 31

Tue, 10 Mar 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260310/26140236.html

Form 10-K ADC Therapeutics SA For: Dec 31

Tue, 10 Mar 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260310/26140083.html

Form 10-K ADC Therapeutics SA For: Dec 31

Tue, 10 Mar 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260310/26140083.html

Form 8-K ADC Therapeutics SA For: Mar 10

Tue, 10 Mar 2026 07:58:00 -0400

si-local-file:///var/storage/secattach/20260310/26135487.html

Form 8-K ADC Therapeutics SA For: Mar 10

Tue, 10 Mar 2026 07:58:00 -0400

si-local-file:///var/storage/secattach/20260310/26135487.html

ADC Therapeutics SA (ADCT) Tops Q4 EPS by 20c

Tue, 10 Mar 2026 07:35:53 -0400

ADC Therapeutics SA (NYSE: ADCT) reported Q4 EPS of ($0.09), $0.20 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $23.06 million versus the consensus estimate of $19.11 million.

For earnings history and earnings-related data on ADC Therapeutics SA (ADCT) click here.

ADC Therapeutics posts $73.6M in 2025 revenue, expects LOTIS-5 data in Q2 2026

Tue, 10 Mar 2026 07:30:48 -0400

ADC Therapeutics SA (NYSE: ADCT) reported net product revenue of $73.6 million for full year 2025, compared to $69.3 million in 2024, according to a company statement released on March 10, 2026.

The commercial-stage biotechnology company, which focuses on antibody drug conjugates, expects topline data from its LOTIS-5 Phase 3 trial in the second quarter of 2026. The trial evaluates ZYNLONTA in combination with rituximab for patients with relapsed or refractory diffuse large B-cell lymphoma.

Fourth quarter 2025 net product revenue reached $22.3 million, up from $16.4 million in the same period of 2024. The company attributed the quarterly increase to customer

ADC Therapeutics posts $73.6M in 2025 revenue, expects LOTIS-5 data in Q2 2026

Tue, 10 Mar 2026 07:30:48 -0400

ADC Therapeutics SA (NYSE: ADCT) reported net product revenue of $73.6 million for full year 2025, compared to $69.3 million in 2024, according to a company statement released on March 10, 2026.

Fourth quarter 2025 net product revenue reached $22.3 million, up from $16.4 million in the same period of 2024. The company attributed the quarterly increase to customer

ADC Therapeutics posts $73.6M in 2025 revenue, expects LOTIS-5 data in Q2 2026

Tue, 10 Mar 2026 07:30:48 -0400

ADC Therapeutics SA (NYSE: ADCT) reported net product revenue of $73.6 million for full year 2025, compared to $69.3 million in 2024, according to a company statement released on March 10, 2026.

Fourth quarter 2025 net product revenue reached $22.3 million, up from $16.4 million in the same period of 2024. The company attributed the quarterly increase to customer

ADC Therapeutics posts $73.6M in 2025 revenue, expects LOTIS-5 data in Q2 2026

Tue, 10 Mar 2026 07:30:48 -0400

ADC Therapeutics SA (NYSE: ADCT) reported net product revenue of $73.6 million for full year 2025, compared to $69.3 million in 2024, according to a company statement released on March 10, 2026.

Fourth quarter 2025 net product revenue reached $22.3 million, up from $16.4 million in the same period of 2024. The company attributed the quarterly increase to customer

ADC Therapeutics posts $73.6M in 2025 revenue, expects LOTIS-5 data in Q2 2026

Tue, 10 Mar 2026 07:30:48 -0400

ADC Therapeutics SA (NYSE: ADCT) reported net product revenue of $73.6 million for full year 2025, compared to $69.3 million in 2024, according to a company statement released on March 10, 2026.

Fourth quarter 2025 net product revenue reached $22.3 million, up from $16.4 million in the same period of 2024. The company attributed the quarterly increase to customer

ADC Therapeutics posts $73.6M in 2025 revenue, expects LOTIS-5 data in Q2 2026

Tue, 10 Mar 2026 07:30:48 -0400

ADC Therapeutics SA (NYSE: ADCT) reported net product revenue of $73.6 million for full year 2025, compared to $69.3 million in 2024, according to a company statement released on March 10, 2026.

Fourth quarter 2025 net product revenue reached $22.3 million, up from $16.4 million in the same period of 2024. The company attributed the quarterly increase to customer

ADC Therapeutics posts $73.6M in 2025 revenue, expects LOTIS-5 data in Q2 2026

Tue, 10 Mar 2026 07:30:48 -0400

ADC Therapeutics SA (NYSE: ADCT) reported net product revenue of $73.6 million for full year 2025, compared to $69.3 million in 2024, according to a company statement released on March 10, 2026.

Fourth quarter 2025 net product revenue reached $22.3 million, up from $16.4 million in the same period of 2024. The company attributed the quarterly increase to customer

ADC Therapeutics posts $73.6M in 2025 revenue, expects LOTIS-5 data in Q2 2026

Tue, 10 Mar 2026 07:30:48 -0400

ADC Therapeutics SA (NYSE: ADCT) reported net product revenue of $73.6 million for full year 2025, compared to $69.3 million in 2024, according to a company statement released on March 10, 2026.

Fourth quarter 2025 net product revenue reached $22.3 million, up from $16.4 million in the same period of 2024. The company attributed the quarterly increase to customer

ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update

Tue, 10 Mar 2026 07:30:00 -0400

LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end 2026

Recent amendment to HealthCare Royalty financing agreement increases strategic flexibility

Fourth quarter and full year 2025 net product revenue of approximately $22.3M and $73.6M, respectively

Cash and cash equivalents of $261.3M as of December 31, 2025, provide expected cash runway at least into 2028

Company to host conference call today at 8:30 a.m. EDT

LAUSANNE, Switzerland, March 10, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and

ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update

Tue, 10 Mar 2026 07:30:00 -0400

LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end 2026

Recent amendment to HealthCare Royalty financing agreement increases strategic flexibility

Fourth quarter and full year 2025 net product revenue of approximately $22.3M and $73.6M, respectively

Cash and cash equivalents of $261.3M as of December 31, 2025, provide expected cash runway at least into 2028

Company to host conference call today at 8:30 a.m. EDT

LAUSANNE, Switzerland, March 10, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and

ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update

Tue, 10 Mar 2026 07:30:00 -0400

LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end 2026

Recent amendment to HealthCare Royalty financing agreement increases strategic flexibility

Fourth quarter and full year 2025 net product revenue of approximately $22.3M and $73.6M, respectively

Cash and cash equivalents of $261.3M as of December 31, 2025, provide expected cash runway at least into 2028

Company to host conference call today at 8:30 a.m. EDT

LAUSANNE, Switzerland, March 10, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and

ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update

Tue, 10 Mar 2026 07:30:00 -0400

LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end 2026

Recent amendment to HealthCare Royalty financing agreement increases strategic flexibility

Fourth quarter and full year 2025 net product revenue of approximately $22.3M and $73.6M, respectively

Cash and cash equivalents of $261.3M as of December 31, 2025, provide expected cash runway at least into 2028

Company to host conference call today at 8:30 a.m. EDT

LAUSANNE, Switzerland, March 10, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and

ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update

Tue, 10 Mar 2026 07:30:00 -0400

LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end 2026

Recent amendment to HealthCare Royalty financing agreement increases strategic flexibility

Fourth quarter and full year 2025 net product revenue of approximately $22.3M and $73.6M, respectively

Cash and cash equivalents of $261.3M as of December 31, 2025, provide expected cash runway at least into 2028

Company to host conference call today at 8:30 a.m. EDT

LAUSANNE, Switzerland, March 10, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and

ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update

Tue, 10 Mar 2026 07:30:00 -0400

LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end 2026

Recent amendment to HealthCare Royalty financing agreement increases strategic flexibility

Fourth quarter and full year 2025 net product revenue of approximately $22.3M and $73.6M, respectively

Cash and cash equivalents of $261.3M as of December 31, 2025, provide expected cash runway at least into 2028

Company to host conference call today at 8:30 a.m. EDT

LAUSANNE, Switzerland, March 10, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and

ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update

Tue, 10 Mar 2026 07:30:00 -0400

LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end 2026

Recent amendment to HealthCare Royalty financing agreement increases strategic flexibility

Fourth quarter and full year 2025 net product revenue of approximately $22.3M and $73.6M, respectively

Cash and cash equivalents of $261.3M as of December 31, 2025, provide expected cash runway at least into 2028

Company to host conference call today at 8:30 a.m. EDT

LAUSANNE, Switzerland, March 10, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and

ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update

Tue, 10 Mar 2026 07:30:00 -0400

LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end 2026

Recent amendment to HealthCare Royalty financing agreement increases strategic flexibility

Fourth quarter and full year 2025 net product revenue of approximately $22.3M and $73.6M, respectively

Cash and cash equivalents of $261.3M as of December 31, 2025, provide expected cash runway at least into 2028

Company to host conference call today at 8:30 a.m. EDT

LAUSANNE, Switzerland, March 10, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and